Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies
Journal Article
·
· Journal of Nuclear Medicine
OSTI ID:430939
- Univ. of California Davis Medical Center, Sacramento, CA (United States)
Tracer pharmacokinetic studies are often used in treatment planning for radionuclide therapy including radioimmunotherapy. This study evaluates the validity of using tracer studies to predict radiation doses from therapy with the same radiolabeled antibody. Quantitative imaging and blood radioactivity were used to obtain the pharmacokinetics and radiation doses that were delivered to the total body, blood, marrow, lungs, liver, kidneys, thyroid, spleen and tumors. 34 refs., 2 figs., 2 tabs.
- DOE Contract Number:
- FG03-84ER60233
- OSTI ID:
- 430939
- Journal Information:
- Journal of Nuclear Medicine, Journal Name: Journal of Nuclear Medicine Journal Issue: 12 Vol. 37; ISSN 0161-5505; ISSN JNMEAQ
- Country of Publication:
- United States
- Language:
- English
Similar Records
Extracorporeal adsorption therapy: A Method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies.
How well does the diagnostic study predict red marrow dose in radioimmunotherapy patients challenged with interferon?
Biodistribution of Yttrium-90-Labeled Anti-CD45 Antibody in a Nonhuman Primate Model
Journal Article
·
Tue Apr 01 00:00:00 EDT 2008
· Cancer Biotherapy & Radiopharmaceuticals, 23(2):181-191
·
OSTI ID:934881
How well does the diagnostic study predict red marrow dose in radioimmunotherapy patients challenged with interferon?
Journal Article
·
Sun May 01 00:00:00 EDT 1994
· Journal of Nuclear Medicine
·
OSTI ID:197982
Biodistribution of Yttrium-90-Labeled Anti-CD45 Antibody in a Nonhuman Primate Model
Journal Article
·
Fri Jan 14 23:00:00 EST 2005
· Clinical Cancer Research
·
OSTI ID:15016365